Clinical Trial Update: Evaluation of Denosumab in Combination With Immune Checkpoint Inhibitors in Patients With Unresectable or Metastatic Melanoma [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial updates evaluating denosumab in combination with immune checkpoint inhibitors in unresectable or metastatic melanoma (Phase 1/Phase 2).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Denosumab (denosumab)

Snippet

Sponsor: Melanoma and Skin Cancer Trials Limited | Conditions: Melanoma Stage Iv, Melanoma Stage Iii | Phase 1, Phase 2 | Status: UNKNOWN